Editorial Commentary
Maintenance strategies in first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer—one size does not fit all
AME Clinical Trials Review
2024;
2:
61
(25 August 2024)
Editorial Commentary
Navigating the future of axillary surgery in HER2+ breast cancer: insights and opportunities for change
AME Clinical Trials Review
2024;
2:
60
(25 August 2024)
Editorial Commentary
Concurrent radiotherapy with capecitabine and pyrotinib in patients with HER2-positive breast cancer and brain metastases
AME Clinical Trials Review
2024;
2:
59
(25 August 2024)
Editorial Commentary
Chemo-immunotherapy on localized gastroesophageal/gastric adenocarcinoma—hope or delusion?
AME Clinical Trials Review
2024;
2:
58
(25 August 2024)
Editorial Commentary
Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KRYSTAL clear?
AME Clinical Trials Review
2024;
2:
57
(25 August 2024)
Editorial Commentary
Precision oncology in small-cell lung cancer: a tough nut to crack
AME Clinical Trials Review
2024;
2:
56
(25 August 2024)
Editorial Commentary
Beyond PACIFIC: efficacy of the dual inhibition of TGF-β and PD-L1 for stage III non-small cell lung cancer concurrent chemoradiotherapy treatment
AME Clinical Trials Review
2024;
2:
55
(25 August 2024)
Editorial Commentary
Exploring novel combinations in the treatment of relapsed ovarian cancer: the MEDIOLA trial results
AME Clinical Trials Review
2024;
2:
54
(25 August 2024)
Editorial Commentary
Expanding the horizons of suspected acute coronary syndrome management: insights from the RAPID-CTCA trial
AME Clinical Trials Review
2024;
2:
53
(25 August 2024)
Editorial Commentary
Combination and precision: ingredients for success in advanced gastric cancer
AME Clinical Trials Review
2024;
2:
52
(25 August 2024)
Editorial Commentary
Can compartment-based complete mesocolic excision improve outcomes in patients with right colon cancer with metastatic D3 nodes?
AME Clinical Trials Review
2024;
2:
51
(25 August 2024)
Editorial Commentary
Nanoparticle-based drug delivery in advanced pancreatic ductal adenocarcinoma: is it time to deliver yet?
AME Clinical Trials Review
2024;
2:
50
(25 August 2024)
Editorial Commentary
Personalized neoantigen vaccines for patients with advanced hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
49
(25 August 2024)
Editorial Commentary
Polo-like kinase 1 inhibitors in refractory colorectal cancer: deciphering the myth of synthetic lethality
AME Clinical Trials Review
2024;
2:
48
(25 August 2024)
Editorial Commentary
Precision combination therapies: shaping the future management of advanced hepatocellular carcinoma?
AME Clinical Trials Review
2024;
2:
47
(25 August 2024)
Editorial Commentary
Multisegmented fully covered esophageal stent: a step to the side
AME Clinical Trials Review
2024;
2:
46
(25 August 2024)
Editorial Commentary
Prolonging anticoagulation after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) patients: still looking for the RIGHT path
AME Clinical Trials Review
2024;
2:
45
(25 August 2024)
Editorial Commentary
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
AME Clinical Trials Review
2024;
2:
44
(25 August 2024)
Review Article
Prediction of lymphatic invasion for patients with early gastric cancer: a review
AME Clinical Trials Review
2024;
2:
43
(25 August 2024)
Editorial Commentary
Improving the efficacy of immunotherapy in patients with advanced or metastatic urothelial carcinoma: a new role for tyrosine kinase inhibitors in the treatment paradigm?
AME Clinical Trials Review
2024;
2:
42
(25 June 2024)
Editorial Commentary
Hyperthermic intraperitoneal chemotherapy in colorectal cancer: is COLOPEC just another brick in the wall?
AME Clinical Trials Review
2024;
2:
41
(25 June 2024)
Editorial Commentary
Targeting TIGIT in lung cancer: will it stick to the wall?
AME Clinical Trials Review
2024;
2:
40
(25 June 2024)
Editorial Commentary
Yes to adjuvant osimertinib therapy in EGFR-mutated stage IB–IIIA non-small cell lung cancer post resection, but for how long? (ADAURA/NCT02511106)
AME Clinical Trials Review
2024;
2:
39
(25 June 2024)
Editorial Commentary
Second-line nivolumab with paclitaxel in biomarker-enriched gastric cancer: not all biomarkers are created equal but is the question even relevant anymore?
AME Clinical Trials Review
2024;
2:
38
(25 June 2024)
Editorial Commentary
Advancing neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC): commentary on the Lung Cancer Mutation Consortium 3 trial (LCMC3)
AME Clinical Trials Review
2024;
2:
37
(25 June 2024)
Editorial Commentary
Judicious use of coronary computed tomography angiography reduces major procedure-related complications in patients aged <65 years with stable chest pain
AME Clinical Trials Review
2024;
2:
36
(25 June 2024)
Editorial Commentary
Prostate-specific membrane antigen (PSMA) radio-guided surgery in prostate cancer: expanding the spectrum of tracers and technologies for patient-tailored molecular-guided surgery
AME Clinical Trials Review
2024;
2:
35
(25 June 2024)
Editorial Commentary
Induction therapy for acute myeloid leukemia: still nothing beyond 7+3?
AME Clinical Trials Review
2024;
2:
34
(25 June 2024)
Editorial Commentary
The Butterfly effect—will the MARIPOSA-2 study alter the trajectory of EGFR mutated non-small cell lung cancer (NSCLC)
AME Clinical Trials Review
2024;
2:
33
(25 June 2024)
Editorial Commentary
Ripretinib as a second-line therapy for advanced gastrointestinal stromal tumors in the era of precision medicine
AME Clinical Trials Review
2024;
2:
32
(25 June 2024)